Stock Analyst Note
GSK Earnings: Strong Sales and Operating Results Support Undervalued Stock
GSK reported first-quarter results largely in line with our expectations, and we are holding firm to our $54 fair value estimate. We continue to view GSK as undervalued with the market not fully appreciating the company’s solid product portfolio that is driving steady growth and securing a wide moat.